scholarly journals Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft by18F-FLT MicroPET/CT Imaging

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Xiao Bao ◽  
Ming-Wei Wang ◽  
Yong-Ping Zhang ◽  
Ying-Jian Zhang
Keyword(s):  
Treatment Response ◽  
Therapy Response ◽  
Immunohistochemical Analysis ◽  
Ct Imaging ◽  
Tumor Xenograft ◽  
Control Group ◽  
Early Therapy ◽  
Flt Pet ◽  
Early Treatment Response ◽  
U87mg Tumor

Aim. It was aimed to monitor early treatment response of Sunitinib in U87MG models mimicking glioblastoma multiforme by longitudinal18F-FLT microPET/CT imaging in this study.Methods. U87MG tumor mice were intragastrically injected with Sunitinib at a dose of 80 mg/kg for consecutive 7 days.18F-FLT microPET/CT scans were acquired on days 0, 1, 3, 7, and 13 after therapy. Tumor sizes and body weight were measured. Tumor samples were collected for immunohistochemical analysis of proliferation and microvessel density (MVD) with anti-Ki67 and anti-CD31, respectively.Results. The uptake ratios of tumor to the contralateral muscle (T/M) of18F-FLT in the Sunitinib group decreased from baseline to day 3 (T/M0= 2.98 ± 0.33; T/M3= 2.23 ± 0.36;P<0.001), reached the bottom on day 7 (T/M7= 1.96 ± 0.35;P<0.001), and then recovered on day 13. The T/M of18F-FLT uptake in the control group remained around 3.0. There was no difference for the tumor size between both groups until day 11.18F-FLT uptakes of tumor were correlated with Ki67 staining index and MVD.Conclusion. Early therapy response to Sunitinib could be predicted via18F-FLT PET, which will contribute to monitoring antiangiogenesis treatment.

scholarly journals Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications

2018 ◽  
pp. 1008-1018 ◽  
Author(s):  
Kaustav Bera ◽  
Vamsidhar Velcheti ◽  
Anant Madabhushi
Keyword(s):  
Treatment Response ◽  
Treatment Effectiveness ◽  
Quantitative Imaging ◽  
Therapy Response ◽  
Response To Therapy ◽  
Imaging Features ◽  
Response Evaluation ◽  
Current Standard ◽  
Trimodality Therapy ◽  
Early Therapy

The current standard of Response Evaluation Criteria in Solid Tumors (RECIST)–based tumor response evaluation is limited in its ability to accurately monitor treatment response. Radiomics, an approach involving computerized extraction of several quantitative imaging features, has shown promise in predicting as well as monitoring response to therapy. In this article, we provide a brief overview of radiomic approaches and the various analytical methods and techniques, specifically in the context of predicting and monitoring treatment response for non–small cell lung cancer (NSCLC). We briefly summarize some of the various types of radiomic features, including tumor shape and textural patterns, both within the tumor and within the adjacent tumor microenvironment. Additionally, we also discuss work in delta-radiomics or change in radiomic features (e.g., texture within the nodule) across longitudinally interspersed images in time for monitoring changes in therapy. We discuss the utility of these approaches for NSCLC, specifically the role of radiomics as a prognostic marker for treatment effectiveness and early therapy response, including chemoradiation, immunotherapy, and trimodality therapy.

scholarly journals Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study

2016 ◽  
Vol 9 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Jacob Antunes ◽  
Satish Viswanath ◽  
Mirabela Rusu ◽  
Laia Valls ◽  
Christopher Hoimes ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Treatment Response ◽  
Early Treatment ◽  
Renal Cell ◽  
Proof Of Concept ◽  
Concept Study ◽  
Flt Pet ◽  
Early Treatment Response

scholarly journals 18F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Antonella Stefanelli ◽  
Giorgio Treglia ◽  
Paoletta Mirk ◽  
Barbara Muoio ◽  
Alessandro Giordano
Keyword(s):  
Tyrosine Kinase ◽  
Treatment Response ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Therapy Response ◽  
Ct Imaging ◽  
Stromal Tumors

Aim. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is a powerful tool for staging and defining “good responders” to chemotherapy in tumor setting. Gastrointestinal stromal tumors (GISTs) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib, a tyrosine kinase inhibitor agent. Some GIST patients become refractory to imatinib; therefore, other tyrosine kinase inhibitors or concomitant chemotherapy may be considered for treatment. The aim of this paper is to assess if 18F-FDG PET imaging is a useful tool to evaluate treatment response to new chemotherapies beyond imatinib for GIST patients. Methods. We performed a review of the literature about the role of 18F-FDG PET in the evaluation of treatment response to new chemotherapies beyond imatinib for GIST patients. Results and Conclusions. 18F-FDG PET seems to be able to assess therapy response earlier than computed tomography (CT) imaging in imatinib refractory GIST patients treated with other agents. However, a dual modality PET-CT imaging is recommendable to achieve a better detection of all lesions.

35 oral: FLT-PET-CT for Early Treatment Response Monitoring in Head and Neck Tumours

2010 ◽  
Vol 94 ◽  
pp. S14
Author(s):  
E. Troost ◽  
J. Bussink ◽  
A. Hoffmann ◽  
O. Boerman ◽  
W. Oyen ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Response ◽  
Early Treatment ◽  
Response Monitoring ◽  
Head And Neck Tumours ◽  
Flt Pet ◽  
Early Treatment Response ◽  
Pet Ct

Assessment of Early Therapy Response with 18F-FLT PET in Glioblastoma Multiforme

2014 ◽  
Vol 39 (10) ◽  
pp. e431-e432 ◽  
Author(s):  
Matthew J. Oborski ◽  
Emre Demirci ◽  
Charles M. Laymon ◽  
Frank S. Lieberman ◽  
James M. Mountz
Keyword(s):  
Glioblastoma Multiforme ◽  
Therapy Response ◽  
Early Therapy ◽  
Flt Pet

scholarly journals Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Benedikt Feuerecker ◽  
Philipp Biechl ◽  
Christof Seidl ◽  
Frank Bruchertseifer ◽  
Alfred Morgenstern ◽  
...  
Keyword(s):  
Amino Acids ◽  
Cancer Cells ◽  
Treatment Response ◽  
Cell Lines ◽  
Egf Receptor ◽  
Metabolic Response ◽  
Gas Chromatography Mass Spectrometry ◽  
Alpha Emitter ◽  
Early Treatment Response ◽  
Bladder Cancer Cells

AbstractEvaluation of treatment response is among the major challenges in modern oncology. We herein used a monoclonal antibody targeting the EGF receptor (EGFR) labelled with the alpha emitter 213Bi (213Bi-anti-EGFR-MAb). EJ28Luc (bladder) and LN18 (glioma) cancer cells, both overexpressing EGFR, were incubated for 3 h with the radioimmunoconjugate. To assess the responses in the core carbon metabolism upon this treatment, these cancer cell lines were subsequently cultivated for 18 h in the presence of [U-13C6]glucose. 13C-enrichment and isotopologue profiles of key amino acids were monitored by gas chromatography–mass spectrometry (GC/MS), in order to monitor the impacts of the radionuclide-treatment upon glucose metabolism. In comparison to untreated controls, treatment of EJ28Luc cells with 213Bi-anti-EGFR-MAb resulted in a significantly decreased incorporation of 13C from [U-13C6]glucose into alanine, aspartate, glutamate, glycine, proline and serine. In sharp contrast, the same amino acids did not display less 13C-enrichments during treatment of the LN18 cells. The data indicate early treatment response of the bladder cancer cells, but not of the glioma cells though cell lines were killed following 213Bi-anti-EGFR-MAb treatment. The pilot study shows that the 13C-labelling approach is a valid tool to assess the responsiveness of cancer cells upon radionuclide-treatment in considerable metabolic detail.

scholarly journals Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-lactamase-producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study

Antibiotics ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 665
Author(s):  
Lena Herrmann ◽  
Aurelia Kimmig ◽  
Jürgen Rödel ◽  
Stefan Hagel ◽  
Norman Rose ◽  
...  
Keyword(s):  
Cohort Study ◽  
Treatment Outcomes ◽  
Treatment Response ◽  
Sofa Score ◽  
Early Treatment ◽  
Primary Outcome ◽  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Early Treatment Response

The Gram-negative bacilli Serratia spp., Providencia spp., Morganella morganii, Citrobacter freundii complex, Enterobacter spp. and Klebsiella aerogenes are common Enterobacterales that may harbor inducible chromosomal AmpC beta-lactamase genes. The purpose of the present study was to evaluate treatment outcomes and identify predictors of early treatment response in patients with bloodstream infection caused by potential AmpC beta-lactamase-producing Enterobacterales (SPICE-BSI). This cohort study included adult patients with SPICE-BSI hospitalized between 01/2011 and 02/2019. The primary outcome was early treatment response 72 h after the start of active treatment, defined as survival, hemodynamic stability, improved or stable SOFA score, resolution of fever and leukocytosis and microbiologic resolution. Among 295 included patients, the most common focus was the lower respiratory tract (27.8%), and Enterobacter spp. (n = 155) was the main pathogen. The early treatment response rate was significantly lower (p = 0.006) in the piperacillin/tazobactam group (17/81 patients, 21.0%) than in the carbapenem group (40/82 patients, 48.8%). Independent negative predictors of early treatment response (p < 0.02) included initial SOFA score, liver comorbidity and empiric piperacillin/tazobactam treatment. In vitro piperacillin/tazobactam resistance was detected in three patients with relapsed Enterobacter-BSI and initial treatment with piperacillin/tazobactam. In conclusion, our findings show that piperacillin/tazobactam might be associated with early treatment failure in patients with SPICE-BSI.

scholarly journals Predicting language treatment response in bilingual aphasia using neural network-based patient models

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Uli Grasemann ◽  
Claudia Peñaloza ◽  
Maria Dekhtyar ◽  
Risto Miikkulainen ◽  
Swathi Kiran
Keyword(s):  
Treatment Response ◽  
Language Impairment ◽  
Computational Models ◽  
Therapy Response ◽  
Therapy Outcomes ◽  
Language Therapy ◽  
Behavioral Profile ◽  
Bilingual Aphasia ◽  
Model Training ◽  
Cross Language

AbstractPredicting language therapy outcomes in bilinguals with aphasia (BWA) remains challenging due to the multiple pre- and poststroke factors that determine the deficits and recovery of their two languages. Computational models that simulate language impairment and treatment outcomes in BWA can help predict therapy response and identify the optimal language for treatment. Here we used the BiLex computational model to simulate the behavioral profile of language deficits and treatment response of a retrospective sample of 13 Spanish-English BWA who received therapy in one of their languages. Specifically, we simulated their prestroke naming ability and poststroke naming impairment in each language, and their treatment response in the treated and the untreated language. BiLex predicted treatment effects accurately and robustly in the treated language and captured different degrees of cross-language generalization in the untreated language in BWA. Our cross-validation approach further demonstrated that BiLex generalizes to predict treatment response for patients whose data were not used in model training. These findings support the potential of BiLex to predict therapy outcomes for BWA and suggest that computational modeling may be helpful to guide individually tailored rehabilitation plans for this population.

Sign in / Sign up

Export Citation Format

Share Document